Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Influence of Subclinical Atherosclerosis Burden and Progression on Mortality.

  • Fuster, Valentin
  • García-Álvarez, Ana
  • Devesa, Ana
  • Mass, Virginia
  • Owen, Ruth
  • Quesada, Antonio
  • Fuster, José J
  • García-Lunar, Inés
  • Pocock, Stuart
  • Sánchez-González, Javier
  • Sartori, Samantha
  • Peyra, Carlos
  • Andres, Vicente
  • Muntendam, Pieter
  • Ibanez, Borja
Atherosclerosis is a dynamic process. There is little evidence regarding whether quantification of atherosclerosis extent and progression, particularly in the carotid artery, in asymptomatic individuals predicts all-cause mortality. This study sought to evaluate the independent predictive value (beyond cardiovascular risk factors) of subclinical atherosclerosis burden and progression and all-cause mortality. A population of 5,716 asymptomatic U.S. adults (mean age 68.9 years, 56.7% female) enrolled between 2008 and 2009 in the BioImage (A Clinical Study of Burden of Atherosclerotic Disease in an At Risk Population) study underwent examination by vascular ultrasound to quantify carotid plaque burden (cPB) (the sum of right and left carotid plaque areas) and by computed tomography for coronary artery calcium (CAC). Follow-up carotid vascular ultrasound was performed on 732 participants a median of 8.9 years after the baseline exam. All participants were followed up for all-cause mortality, the primary outcome. Trend HRs are the per-tertile increase in each variable. Over a median 12.4 years' follow-up, 901 (16%) participants died. After adjustment for cardiovascular risk factors and background medication, baseline cPB and CAC score were both significantly associated with all-cause mortality (fully adjusted trend HR: 1.23; 95% CI: 1.16-1.32; and HR: 1.15; 95% CI: 1.08-1.23), respectively (both P < 0.001), thus providing additional prognostic value. cPB performed better than CAC score. In participants with a second vascular ultrasound evaluation, median cPB progressed from 29.2 to 91.3 mm. cPB progression was significantly associated with all-cause mortality after adjusting for cardiovascular risk factors and baseline cPB (HR: 1.03; 95% CI: 1.01-1.04 per absolute 10-mm change; P = 0.01). Subclinical atherosclerosis burden (cPB and CAC) in asymptomatic individuals was independently associated with all-cause mortality. Moreover, atherosclerosis progression was independently associated with all-cause mortality.
Repisalud
Publication Artículo científico (JournalArticle)

Coronary Microvascular Function in Asymptomatic Middle-Aged Individuals With Cardiometabolic Risk Factors.

  • Devesa, Ana
  • Fuster, Valentin
  • García-Lunar, Inés
  • Oliva, Belén
  • García-Alvarez, Ana
  • Moreno-Arciniegas, Andrea
  • Vazirani, Ravi
  • Pérez-Herreras, Cristina
  • Marina, Pablo
  • Bueno, Héctor
  • Fernández-Friera, Leticia
  • Fernández-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
  • Devesa, Ana
  • Fuster, Valentin
  • García-Lunar, Inés
  • Oliva, Belén
  • García-Alvarez, Ana
  • Moreno-Arciniegas, Andrea
  • Vazirani, Ravi
  • Pérez-Herreras, Cristina
  • Marina, Pablo
  • Bueno, Héctor
  • Fernández-Friera, Leticia
  • Fernández-Ortiz, Antonio
  • Sanchez-Gonzalez, Javier
  • Ibanez, Borja
In patients with ischemic heart disease, coronary microvascular dysfunction is associated with cardiovascular risk factors and poor prognosis; however, data from healthy individuals are scarce. The purpose of this study was to assess the impact of cardiovascular risk factors and subclinical atherosclerosis on coronary microvascular function in middle-aged asymptomatic individuals. Myocardial perfusion was measured at rest and under stress using cardiac magnetic resonance in 453 individuals and used to generate myocardial blood flow (MBF) maps and calculate myocardial perfusion reserve (MPR). Subclinical atherosclerosis was assessed using 3-dimensional vascular ultrasound of the carotid and femoral arteries and coronary artery calcium scoring at baseline and at 3-year follow-up. Median participant age was 52.6 years (range: 48.9-55.8 years), and 84.5% were male. After adjusting for age and sex, rest MBF was directly associated with the number of the metabolic syndrome components present (elevated waist circumference, systolic and diastolic blood pressure, fasting glucose, and triglycerides and low high-density lipoprotein cholesterol), insulin resistance (homeostatic model assessment for insulin resistance), and presence of diabetes. MPR was reduced in the presence of several metabolic syndrome components, elevated homeostatic model assessment for insulin resistance, and diabetes. Stress MBF was inversely associated with coronary artery calcium presence and with global plaque burden. Higher stress MBF and MPR were associated with less atherosclerosis progression (increase in plaque volume) at 3 years. In asymptomatic middle-aged individuals free of known cardiovascular disease, the presence of cardiometabolic risk factors and systemic (poly-vascular) subclinical atherosclerosis are associated with impaired coronary microvascular function. Better coronary microvascular function reduces atherosclerosis progression at follow-up. (Progression of Early Subclinical Atherosclerosis [PESA]; NCT01410318).
Repisalud
Publication Artículo científico (JournalArticle)

Anthracycline Cardiotoxicity Induces Progressive Changes in Myocardial Metabolism and Mitochondrial Quality Control: Novel Therapeutic Target.

  • Díaz-Guerra, Anabel
  • Villena-Gutierrez, Rocio
  • Clemente-Moragón, Agustín
  • Gomez, Monica
  • Oliver, Eduardo
  • Fernández-Tocino, Miguel
  • Galan-Arriola, Carlos
  • Cádiz, Laura
  • Ibáñez, Borja
BACKGROUND Anthracycline-induced cardiotoxicity (AIC) debilitates quality of life in cancer survivors. Serial characterizations are lacking of the molecular processes occurring with AIC. OBJECTIVES The aim of this study was to characterize AIC progression in a mouse model from early (subclinical) to advanced heart failure stages, with an emphasis on cardiac metabolism and mitochondrial structure and function. METHODS CD1 mice received 5 weekly intraperitoneal doxorubicin injections (5 mg/kg) and were followed by serial echocardiography for 15 weeks. At 1, 9, and 15 weeks after the doxorubicin injections, mice underwent fluorodeoxyglucose positron emission tomography, and hearts were extracted for microscopy and molecular analysis. RESULTS Cardiac atrophy was evident at 1 week post-doxorubicin (left ventricular [LV] mass 117 ± 26 mg vs 97 ± 25 mg at baseline and 1 week, respectively; P < 0.001). Cardiac mass nadir was observed at week 3 post-doxorubicin (79 ± 16 mg; P = 0.002 vs baseline), remaining unchanged thereafter. Histology confirmed significantly reduced cardiomyocyte area (167 ± 19 μm2 in doxorubicin-treated mice vs 211 ± 26 μm2 in controls; P = 0.004). LV ejection fraction declined from week 6 post-doxorubicin (49% ± 9% vs 61% ± 9% at baseline; P < 0.001) until the end of follow-up at 15 weeks (43% ± 8%; P < 0.001 vs baseline). At 1 week post-doxorubicin, when LV ejection fraction remained normal, reduced cardiac metabolism was evident from down-regulated markers of fatty acid oxidation and glycolysis. Metabolic impairment continued to the end of follow-up in parallel with reduced mitochondrial adenosine triphosphate production. A transient early up-regulation of nutrient-sensing and mitophagy markers were observed, which was associated with mitochondrial enlargement. Later stages, when mitophagy was exhausted, were characterized by overt mitochondrial fragmentation. CONCLUSIONS Cardiac atrophy, global hypometabolism, early transient-enhanced mitophagy, biogenesis, and nutrient sensing constitute candidate targets for AIC prevention.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Unidirectional association of clonal hematopoiesis with atherosclerosis development.

  • Díez-Díez, Miriam
  • Ramos-Neble, Beatriz L
  • de la Barrera, Jorge
  • Silla-Castro, J C
  • Quintas, Ana
  • Vázquez, Enrique
  • Rey-Martín, M Ascensión
  • Izzi, Benedetta
  • Sánchez-García, Lucía
  • García-Lunar, Inés
  • Mendieta, Guiomar
  • Mass, Virginia
  • Gómez-López, Nuria
  • Espadas, Cristina
  • González, Gema
  • Quesada, Antonio J
  • García-Álvarez, Ana
  • Fernández-Ortiz, Antonio
  • Lara-Pezzi, Enrique
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Ibáñez, Borja
  • Andrés, Vicente
  • Fuster, Valentín
  • Fuster, José J
Clonal hematopoiesis, a condition in which acquired somatic mutations in hematopoietic stem cells lead to the outgrowth of a mutant hematopoietic clone, is associated with a higher risk of hematological cancer and a growing list of nonhematological disorders, most notably atherosclerosis and associated cardiovascular disease. However, whether accelerated atherosclerosis is a cause or a consequence of clonal hematopoiesis remains a matter of debate. Some studies support a direct contribution of certain clonal hematopoiesis-related mutations to atherosclerosis via exacerbation of inflammatory responses, whereas others suggest that clonal hematopoiesis is a symptom rather than a cause of atherosclerosis, as atherosclerosis or related traits may accelerate the expansion of mutant hematopoietic clones. Here we combine high-sensitivity DNA sequencing in blood and noninvasive vascular imaging to investigate the interplay between clonal hematopoiesis and atherosclerosis in a longitudinal cohort of healthy middle-aged individuals. We found that the presence of a clonal hematopoiesis-related mutation confers an increased risk of developing de novo femoral atherosclerosis over a 6-year period, whereas neither the presence nor the extent of atherosclerosis affects mutant cell expansion during this timeframe. These findings indicate that clonal hematopoiesis unidirectionally promotes atherosclerosis, which should help translate the growing understanding of this condition into strategies for the prevention of atherosclerotic cardiovascular disease in individuals exhibiting clonal hematopoiesis.
Repisalud
Publication Artículo científico (JournalArticle)

Remote ischemic conditioning protects against anthracycline cardiotoxicity without impairing its antitumor activity.

  • Díaz-Guerra, Anabel
  • Clemente-Moragón, Agustín
  • Pollán, Ángela
  • López-Palomar, Lucía
  • Cádiz, Laura
  • Ibáñez, Borja
Anthracyclines remain a cornerstone of treatment for many cancer types; however, their cardiotoxic potential leads to cardiac dysfunction in a substantial proportion of patients, ultimately compromising long-term quality of life. Few strategies have proven effective in preventing anthracycline-induced cardiotoxicity (AIC). Among them, remote ischemic conditioning (RIC) has emerged as one of the most promising, having shown robust cardioprotective potential in preclinical studies and currently being evaluated in clinical trials. However, it remains unclear whether this intervention, while protecting the heart, could also inadvertently protect tumors from the cytotoxic effects of anthracyclines, thereby reducing their antitumor efficacy. In this study, we investigated whether RIC protects against AIC in a tumor-bearing mouse model, allowing simultaneous assessment of both cardiac and tumoral responses. Cutaneous tumors were induced in CD1 mice using a DMBA/TPA protocol, followed by five weekly intraperitoneal injections of doxorubicin (5 mg/kg). Mice bearing tumors were randomized to receive doxorubicin alone or in combination with weekly RIC (three cycles of 5 min hindlimb ischemia/reperfusion). Longitudinal echocardiography was used to assess cardiac function, while tumor growth, survival, and body weight were monitored throughout the protocol. Doxorubicin treatment reduced overall survival, inhibited tumor growth, and induced left ventricular systolic dysfunction and cardiac atrophy compared with untreated controls. RIC preserved left ventricular ejection fraction, partially attenuated early left ventricular atrophy, and showed a trend towards improved survival, without attenuating the antitumor efficacy of doxorubicin, as tumor suppression remained comparable between treatment groups. These findings demonstrate that RIC preserves cardiac systolic function during anthracycline chemotherapy in tumor-bearing mice without impairing the antitumor efficacy of the drug. The results support RIC as a simple, safe, and low-cost non-pharmacological strategy to mitigate AIC with potential translational relevance for oncology patients.
Repisalud
Publication Artículo científico (JournalArticle)

Update on preclinical models of cancer therapy-related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart.

  • Ghigo, Alessandra
  • Ameri, Pietro
  • Asnani, Aarti
  • Bertero, Edoardo
  • de Boer, Rudolf A
  • Farmakis, Dimitrios
  • González, Arantxa
  • Heymans, Stephane
  • Ibáñez, Borja
  • López-Fernández, Teresa
  • Lyon, Alexander R
  • Pollesello, Piero
  • Rakisheva, Amina
  • Stellos, Konstantinos
  • Streckfuss-Bömeke, Katrin
  • Tocchetti, Carlo Gabriele
  • Thum, Thomas
  • van der Meer, Peter
  • Van Rooij, Eva
  • Ponikowski, Piotr
  • Metra, Marco
  • Rosano, Giuseppe
  • Van Linthout, Sophie
New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the implementation of effective treatments. Therefore, there is a crucial need for appropriate preclinical models to understand the biological basis of their cardiotoxicity. This scientific statement summarizes the preclinical models hitherto used, from in vitro two- and three-dimensional human systems to small and large animals, to pinpoint the molecular mechanisms behind the cardiotoxicity of new-generation anticancer therapies, particularly immunotherapies, and to develop potential cardioprotective strategies. Furthermore, it discusses how preclinical models have contributed to the provocative concept of heart failure being potentially tumorigenic and how the discovery of drugs with both anticancer and cardioprotective actions has revealed a common mechanistic basis for heart failure and cancer. Finally, it discusses the existing gaps between preclinical models and clinical observations in patients, how these discrepancies affect regulatory pathways and the drug development process in cardio-oncology and provides recommendations for closing these gaps.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Cardioprotection strategies for anthracycline cardiotoxicity.

  • Moreno-Arciniegas, Andrea
  • Cádiz, Laura
  • Galán-Arriola, Carlos
  • Clemente-Moragón, Agustín
  • Ibáñez, Borja
Thanks to the fantastic progress in cancer therapy options, there is a growing population of cancer survivors. This success has resulted in a need to focus much effort into improving the quality of life of this population. Cancer and cardiovascular disease share many common risk factors and have an interplay between them, with one condition mechanistically affecting the other and vice versa. Furthermore, widely prescribed cancer therapies have known toxic effects in the cardiovascular system. Anthracyclines are the paradigm of efficacious cancer therapy widely prescribed with a strong cardiotoxic potential. While some cancer therapies cardiovascular toxicities are transient, others are irreversible. There is a growing need to develop cardioprotective therapies that, when used in conjunction with cancer therapies, can prevent cardiovascular toxicity and thus improve long-term quality of life in survivors. The field has three main challenges: (i) identification of the ultimate mechanisms leading to cardiotoxicity to (ii) identify specific therapeutic targets, and (iii) more sensible diagnostic tools to early identify these conditions. In this review we will focus on the cardioprotective strategies tested and under investigation. We will focus this article into anthracycline cardiotoxicity since it is still the agent most widely prescribed, the one with higher toxic effects on the heart, and the most widely studied.
Repisalud
Publication Artículo científico (JournalArticle)

Four-Dimensional Magnetic Resonance Pulmonary Flow Imaging for Assessing Pulmonary Vasculopathy in Patients with Postcapillary Pulmonary Hypertension.

  • Nuche, Jorge
  • Ponz, Inés
  • Sánchez Sánchez, Violeta
  • Bóbeda, Javier
  • Gaitán, Ángel
  • López-Linares, Karen
  • García-Cosío, María Dolores
  • Sarnago Cebada, Fernando
  • González, Javier Sánchez
  • Arribas Ynsaurriaga, Fernando
  • Ruíz-Cabello, Jesús
  • Ibáñez, Borja
  • Delgado, Juan F
Noninvasive techniques for diagnosing combined postcapillary pulmonary hypertension (CpcPH) are unavailable. : To assess the diagnostic performance of cardiac magnetic resonance (CMR)-based four-dimensional (4D)-flow analysis in identifying CpcPH. : Prospective observational study of heart failure (HF) patients with suspected pulmonary hypertension (PH) who underwent simultaneous CMR and right heart catheterization. The 4D-flow biomarkers were calculated using an automatic pipeline. A predictive model including 4D-flow biomarkers associated with CpcPH with a -value < 0.20 was built to determine the diagnostic performance of 4D-flow analysis to identify CpcPH. : A total of 46 HF patients (55.4 ± 14 years, 63% male) with confirmed PH (19 [41%] isolated postcapillary PH [IpcPH], 27 [59%] CpcPH) were included. No differences were found in baseline characteristics, echocardiography, or CMR anatomical and functional parameters, except for a higher Doppler-estimated systolic pulmonary pressure and larger pulmonary artery in CpcPH patients. The 4D-flow CMR analysis was performed in 31 patients (67%). The maximal peak velocity (67.1 [62.2-77.5] cm/s-IpcPH vs. 58.2 [45.8-66.0] cm/s-CpcPH; = 0.021) and maximal helicity (339.9 [290.0-391.8]) cm/s-IpcPH vs. 226.0 (173.5-343.7) cm/s-CpcPH; = 0.026) were significantly lower in patients with CpcPH. A maximal multivariable model including sex, maximal average, and peak velocities, Reynolds number, flow rate, and helicity showed fair diagnostic performance (area under the curve: 0.768 [95%-CI: 0.572-0.963]; sensitivity: 100%; specificity: 55%). : In HF patients with PH, 4D-flow-derived maximal peak velocity and maximal helicity were significantly lower in CpcPH patients. A multiparametric model including maximal 4D-flow-derived biomarkers showed good diagnostic performance for identifying CpcPH.
Repisalud
Publication Artículo científico (JournalArticle)

Bone marrow activation in response to metabolic syndrome and early atherosclerosis

  • Devesa, Ana
  • Lobo-González, Manuel
  • Martínez-Milla, Juan
  • Oliva, Belén
  • García-Lunar, Inés
  • Mastrangelo, Annalaura
  • España, Samuel
  • Sanz, Javier
  • Mendiguren, José M
  • Bueno, Hector
  • Fuster, Jose J.
  • Andres, Vicente
  • Fernández-Ortiz, Antonio
  • Sancho, David
  • Fernández-Friera, Leticia
  • Sanchez-Gonzalez, Javier
  • Rossello, Xavier
  • Ibáñez, Borja
  • Fuster, Valentin
Aims: Experimental studies suggest that increased bone marrow (BM) activity is involved in the association between cardiovascular risk factors and inflammation in atherosclerosis. However, human data to support this association are sparse. The purpose was to study the association between cardiovascular risk factors, BM activation, and subclinical atherosclerosis. Methods and results: Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). Conclusion: In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].Whole body vascular 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI) was performed in 745 apparently healthy individuals [median age 50.5 (46.8-53.6) years, 83.8% men] from the Progression of Early Subclinical Atherosclerosis (PESA) study. Bone marrow activation (defined as BM 18F-FDG uptake above the median maximal standardized uptake value) was assessed in the lumbar vertebrae (L3-L4). Systemic inflammation was indexed from circulating biomarkers. Early atherosclerosis was evaluated by arterial metabolic activity by 18F-FDG uptake in five vascular territories. Late atherosclerosis was evaluated by fully formed plaques on MRI. Subjects with BM activation were more frequently men (87.6 vs. 80.0%, P = 0.005) and more frequently had metabolic syndrome (MetS) (22.2 vs. 6.7%, P < 0.001). Bone marrow activation was significantly associated with all MetS components. Bone marrow activation was also associated with increased haematopoiesis-characterized by significantly elevated leucocyte (mainly neutrophil and monocytes) and erythrocyte counts-and with markers of systemic inflammation including high-sensitivity C-reactive protein, ferritin, fibrinogen, P-selectin, and vascular cell adhesion molecule-1. The associations between BM activation and MetS (and its components) and increased erythropoiesis were maintained in the subgroup of participants with no systemic inflammation. Bone marrow activation was significantly associated with high arterial metabolic activity (18F-FDG uptake). The co-occurrence of BM activation and arterial 18F-FDG uptake was associated with more advanced atherosclerosis (i.e. plaque presence and burden). In apparently healthy individuals, BM 18F-FDG uptake is associated with MetS and its components, even in the absence of systemic inflammation, and with elevated counts of circulating leucocytes. Bone marrow activation is associated with early atherosclerosis, characterized by high arterial metabolic activity. Bone marrow activation appears to be an early phenomenon in atherosclerosis development.[Progression of Early Subclinical Atherosclerosis (PESA); NCT01410318].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Environmental and dietary determinants of metal exposure in four-year-old children from a cohort located in an industrial area (Asturias, Northern Spain)

  • Junqué, Eva
  • Tardón, Adonina
  • Fernandez-Somoano, Ana
  • Grimalt, Joan O.
Urine samples from four-year-old children located in a heavily industrialized zone in Asturias (Spain) were collected between 2009 and 2012 (n = 334). Vanadium (V; median 54 μg/g creatinine), cobalt (Co; 1.0 μg/g c.), nickel (Ni; 3.8 μg/g c.), copper (Cu; 22 μg/g c.), zinc (Zn; 590 μg/g c.), arsenic (As; 64 μg/g c.), selenium (Se; 49 μg/g c.), molybdenum (Mo; 110 μg/g c.), cadmium (Cd; 0.27 μg/g c.), antimony (Sb; 1.0 μg/g c.), cesium (Cs; 14 μg/g c.), barium (Ba; 2.6 μg/g c.), thallium (Tl; 0.55 μg/g c.) and lead (Pb; 1.9 μg/g c.) were analysed. Comparison with children from other sites showed that this Asturias cohort was characterized by high levels of V, As, Sb, Cs and Tl. The concentrations of Co, Ni, Zn, Cu, Mo, Se, Cd, Ba and Pb were within the range of other cohorts. Terrestrial dietary items were most strongly related to increased urinary concentrations of metals in children, e.g., red meat with Ba and Ni, pasta/cereal with Ni and Zn, sweets with Zn, Co, and Cu, eggs with Mo, Cd, and Cs, and dairy products with Co and Sb. Seafood was the second group of dietary items significantly related to increased metals, e.g., shellfish with Ba, Cs, Pb, and V, fatty fish with As, and lean fish with As and Se. In contrast, higher fruit intake was significantly associated with decreased Cu and Sb, and higher legume intake with decreased Cu, Se and Cs. Higher intakes of other dietary items also led to significant decreases in some metals, such as vegetables and lower concentrations of Se and Mo, and dairy products with decreases in Cu and As. These negative correlations implied very low concentrations of the mentioned metals in these foods. Higher exposure to traffic was associated with higher concentrations of Ba, present in brake components. Children living outside urban areas had higher concentrations of Se. No association of metals with smoking in the family was found., The authors would particularly like to thank all the participants for their generous collaboration and the staff from Hospital San Agustin in Aviles for their effort. This study was funded by grants from CIBERESP, FIS-FEDER (PI04/2018, PI09/02311, PI13/02429, PI18/00909), Obra Social Cajastur/Fundación Liberbank and Oviedo University. This paper was also supported by funding from the European Union projects: EDCMET (H2020-HEALTH/0490–825762) and PARC (HLTH-2021-ENVHLTH-3:101057014)., Peer reviewed